New Chairman of the Board for Melanoma Institute Australia
1 March 2017
We are delighted to announce the appointment of Mr Grant King as Chairman of the Board of Melanoma Institute Australia.
Mr King’s appointment follows the retirement of Reg Richardson AM who led the MIA Board for the last 10 years.
“Under Mr Richardson’s leadership the Institute has firmly cemented its reputation as a global luminary in the fight against melanoma, and we are now leading international research which is resulting in innovative new treatments and prolonged life expectancies for even advanced melanoma patients,” said the CEO of MIA Carole Renouf.
“Mr King’s experience in strategy and business development, as well as his interest in community and philanthropic causes, will be critical in galvanising ongoing medical, scientific and government support for melanoma research projects and clinical trials,” she said.
“I am looking forward to joining the team of brilliant minds at Melanoma Institute Australia,” Mr King said. “Their results orientation and dedication to improving outcomes for melanoma patients is an inspiration. This is a special opportunity for Australia to lead the rest of the world in research”.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.